Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $104,300.27 in Stock

Posted by James Conley on Mar 19th, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Andrew Callos sold 1,709 shares of Cytokinetics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $61.03, for a total value of $104,300.27. Following the completion of the transaction, the executive vice president owned 46,149 shares of the company’s stock, valued at approximately $2,816,473.47. The trade was a 3.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Andrew Callos also recently made the following trade(s):

On Wednesday, March 18th, Andrew Callos sold 1,930 shares of Cytokinetics stock. The shares were sold at an average price of $62.07, for a total value of $119,795.10.
On Tuesday, March 17th, Andrew Callos sold 8,542 shares of Cytokinetics stock. The stock was sold at an average price of $62.15, for a total value of $530,885.30.
On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total transaction of $156,779.04.
On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.87, for a total transaction of $1,608,620.00.
On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $61.93, for a total transaction of $928,950.00.
On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total transaction of $55,020.60.
On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $60.28, for a total transaction of $904,200.00.
On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total transaction of $112,590.76.
On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The shares were sold at an average price of $62.44, for a total transaction of $112,953.96.

Cytokinetics Stock Up 0.1%

CYTK opened at $62.19 on Thursday. The company’s 50-day moving average price is $63.80 and its 200 day moving average price is $60.94. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The firm has a market cap of $7.66 billion, a price-to-earnings ratio of -9.52 and a beta of 0.56.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.26) EPS. Research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CYTK. HC Wainwright increased their target price on Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. UBS Group boosted their price target on shares of Cytokinetics from $61.00 to $69.00 and gave the company a “neutral” rating in a report on Friday, March 6th. Bank of America reaffirmed a “neutral” rating on shares of Cytokinetics in a report on Wednesday, February 25th. Truist Financial lifted their price objective on shares of Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. Finally, Mizuho boosted their target price on shares of Cytokinetics from $84.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday. Seventeen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.89.

Read Our Latest Stock Analysis on Cytokinetics

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Mizuho raised its price target on CYTK from $84 to $100 and kept an “outperform” rating — a large upside that supports further buying interest. Mizuho raise
Positive Sentiment: JPMorgan raised its price target slightly (from $74 to $75) and maintained an “overweight” rating, reinforcing institutional confidence. JPMorgan note
Positive Sentiment: Barclays reiterated its Buy rating on Cytokinetics, adding to the cluster of bullish analyst views that support momentum. Barclays article
Neutral Sentiment: Cytokinetics granted inducement awards (options for 8,628 shares and 5,719 RSUs) to five new hires under Nasdaq Rule 5635(c)(4) — standard recruiting compensation that is dilutive over time but not an operational red flag. Inducement grants
Neutral Sentiment: Analytical coverage assessing CYTK valuation after new MYQORZO trial data and safety outcomes is circulating — useful for longer‑term thesis but not a single near‑term catalyst. Valuation analysis
Negative Sentiment: CEO Robert I. Blum sold 36,601 shares on March 17 at an average ~$62.15 (~$2.27M), reducing his stake by ~7.8% — a large insider sale that may be read as executive profit‑taking. CEO Form 4
Negative Sentiment: EVP Fady Ibraham Malik sold 12,033 shares on March 17 at ~$62.15 (~$747.9k), a ~7.25% cut to his holdings. Malik Form 4
Negative Sentiment: EVP Andrew Callos executed several recent sales (including 8,542 shares on Mar 17 at ~$62.15 and 1,930 shares on Mar 18 at ~$62.07), further reducing insider holdings — consistent with ongoing, sizable executive selling. Callos Form 4
Negative Sentiment: EVP Sung Lee sold 4,935 shares on Mar 17 at ~$62.15 (~$306.7k), trimming his stake by ~5.4%. Multiple senior‑level sales together may temper investor enthusiasm despite analyst optimism. Lee Form 4

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CYTK. Bank of Montreal Can increased its holdings in shares of Cytokinetics by 1.2% during the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after purchasing an additional 160 shares during the period. Kennedy Capital Management LLC raised its stake in shares of Cytokinetics by 1.2% during the fourth quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock valued at $838,000 after purchasing an additional 162 shares in the last quarter. UMB Bank n.a. lifted its holdings in Cytokinetics by 10.6% in the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 169 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 171 shares in the last quarter. Finally, Vident Advisory LLC grew its position in Cytokinetics by 1.4% in the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock valued at $1,046,000 after buying an additional 234 shares in the last quarter.

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.